Latest:
Taking a Drink From the Fire Hose
Several colleagues, patients and caregivers nominated Jill May, B.S.N., RN, OCN, for the 2024 Extraordinary Healer Award for her dedicating to caring for those with gastrointestinal cancers.
- About Us
- Advertise / Support
- Editorial Board
- Contact Us
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2025 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Contributors
Jenny Burkholder
Latest:
One Nurse’s Devotion to Cancer Has Healed Many Patients
“I feel her strength, and because of Lorelei — the way she makes me feel comfortable and confident; the way she cares deeply for me, her other patients and colleagues; and her always professional attitude and manner — I realize that, like other obstacles, I will eventually be able to face this, too,” writes one nurse’s patient in an essay nominating her for CURE®’s 2022 Extraordinary Healer award.
Jennifer Cargile, Med, CCC-SLP
Jennifer Cargile, Med, CCC-SLP, is a speech-language pathologist at Cancer Treatment Centers of America Atlanta.
Latest:
Oncology Rehabilitation: An Integral Part of Integrative Care for Head and Neck Cancer Treatment
Head and neck cancer treatments and the subsequent side effects can be overwhelming for patients and their caregivers due to the impact they have on routine activities, writes a speech-language pathologist at Cancer Treatment Center of America Atlanta. However, the expert notes, there are plenty of specialists who can help improve patient quality of life.
Dr. Massimo Cristofanilli
Dr. Massimo Cristofanilli is the director of Breast Medical Oncology, professor of Medicine, and associate director of Precision Oncology at Weill Cornell Medicine; attending physician at New York-Presbyterian.
Latest:
Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.